Brief: Halozyme Announces Argenx Received Positive CHMP Opinion For Vyvgart (Efgartigimod Alfa) Subcutaneous Injection With Enhanze For CIDP
28/04/2025 13:15
April 28 (Reuters) - Halozyme Therapeutics Inc HALO.O: HALOZYME ANNOUNCES ARGENX RECEIVED POSITIVE CHMP OPINION FOR VYVGART® (EFGARTIGIMOD ALFA) SUBCUTANEOUS INJECTION WITH ENHANZE® FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) Source text: ID:nPn49kLV9a Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets